Table 2.
Symptoms experienced by 73 patients with nasopharyngeal-swab confirmed COVID-19
| Characteristic | Female (No., %) |
Male (No., %) |
P-valuesa | Total (No., %; 95% CIb) |
Published Estimates (ref: 19,20) (%) |
|---|---|---|---|---|---|
| Symptoms | |||||
| Cough | 34 (66.7) | 14 (63.6) | 0.80 | 48 (65.8; 53.7–76.5) | 58.3 |
| Fatigue | 28 (54.9) | 16 (72.7) | 0.20 | 44 (60.3; 48.1–71.5) | 34.0 |
| Headache | 26 (51.0) | 5 (22.7) | 0.04 | 31 (42.5; 31.0–54.6) | 11.3 |
| Myalgia | 21 (41.2) | 8 (36.4) | 0.80 | 29 (39.7; 28.5–51.9) | 21.9 |
| Anosmia | 23 (45.1) | 4 (18.2) | 0.04 | 27 (37.0; 26.0–49.1) | 52.7 |
| Fever | 15 (29.4) | 9 (40.9) | 0.42 | 24 (32.9; 22.3–44.9) | 78.4 |
| Breathlessness | 14 (27.5) | 9 (40.9) | 0.28 | 23 (31.5; 21.1–43.4) | 20.6 |
| Anxiety/depression | 17 (33.3) | 7 (31.8) | 1.00 | 24 (32.9; 22.3–44.9) | Not reported |
| Dysgeusia | 13 (25.5) | 5 (22.7) | 1.00 | 18 (24.7; 15.3–36.0) | 43.9 |
| Sputum production | 12 (23.5) | 5 (22.7) | 1.00 | 17 (23.3; 14.2–34.6) | 22.7 |
| Sweats/chills | 14 (27.5) | 3 (13.6) | 0.24 | 17 (23.3; 14.2–34.7) | Not reported |
| Nasal congestion | 12 (23.5) | 4 (18.2) | 0.76 | 16 (21.9; 13.1–33.1) | 4 |
| Sore throat | 11 (21.6) | 5 (22.7) | 1.00 | 16 (21.9; 13.1–33.1) | 11.6 |
| Loss of appetite | 12 (23.5) | 3 (13.6) | 0.53 | 15 (20.5; 12.0–31.6) | 22.7 |
| Rhinorrhea | 12 (23.5) | 3 (13.6) | 0.53 | 15 (20.5; 12.0–31.6) | 7.3 |
| Diarrhea | 9 (17.6) | 2 (9.1) | 0.49 | 11 (15.1; 7.8–25.4) | 7.7 |
| Dizzy/light-headed | 9 (17.6) | 5 (22.7) | 0.75 | 14 (19.2; 10.9–30.1) | 12.1 |
| Nausea/vomiting | 10 (19.6) | 3 (13.6) | 0.71 | 9 (12.3; 5.8–22.1) | 7.8 |
| Chest tightness | 5 (9.8) | 3 (13.6) | 0.69 | 8 (11.0; 4.9–20.5) | 22.9 |
| Tachycardia | 3 (5.9) | 2 (9.1) | 0.63 | 5 (6.8; 2.3–15.3) | Not reported |
| Cold clammy skin | 1 (2.0) | 0 | 1.00 | 1 (1.4; 0.0–7.4) | Not listed |
| Decrease urine Output | 0 | 1 (4.5) | 0.30 | 1 (1.4; 0.0–7.4) | Not listed |
| Hemoptysis | 0 | 1 (4.5) | 0.30 | 1 (1.4; 0.0–7.4) | 0.9 |
| Confusion | 0 | 0 | - | 0 | 9 |
| Cutaneous symptoms | 0 | 0 | - | 0 | 7.8 |
| Additional Symptoms | 20 (39.2) | 2 (9.1) | 0.02 | 22 (30.1; 19.9–42.0) | - |
| Number of symptoms | |||||
| 0 | 2 (3.9) | 3 (13.6) | 5 (6.8; 2.3–15.3) | ||
| 1–3 | 12 (23.5) | 4 (18.2) | 16 (21.9; 13.1–33.1) | ||
| 4–6 | 11 (21.6) | 7 (31.8) | 0.83 | 18 (24.7; 15.3–36.0) | |
| 7–9 | 20 (39.2) | 5 (22.7) | 25 (34.2; 23.5–46.3) | ||
| 10–12 | 4 (7.8) | 3 (13.6) | 7 (9.6; 3.9–18.8) | ||
| ≥ 13 | 2 (4.0) | 0 | 2 (2.7; 0.3–9.6) | ||
| COVID-19 severityc | |||||
| Mild | 48 (94.1) | 16 (72.7) | 0.02 | 64 (87.7; 77.9–94.2 | |
| Moderate | 3 (5.9) | 6 (27.3) | 9 (12.3; 5.8–22.1) |
aFisher exact test.
b95% confidence intervals calculated by Clopper–Pearson method.
cBased on World Health Organization Classification of COVID-19 severity.